T Cell Target/Epitope Discovery & Mapping
JPT offers the largest portfolio of peptide formats for the effective and deep discovery, confirmation, and qualification of T-cell antigen targets, immunodominant epitopes and neo-epitopes. Our fast, cost-effective, high throughput peptide synthesis platforms enable discovery of vaccine targets from a variety of antigens or even pathogenic proteomes in indications such as infectious diseases and cancer. In addition, deep epitope discovery becomes feasible creating tens of thousands of low-cost peptides for functional cellular, binding, mass spectrometric and various other assays.
Benefits of working with JPT
- We develop unique technologies for discovery, therapy and immune monitoring
- We understand your application
- Over 1000 peer reviewed papers with our products
- We are ISO 9001:2015 certified